These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27070168)

  • 1. [A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin].
    Latysheva TV; Latysheva EA; Martynova IA
    Ter Arkh; 2016; 88(4):82-87. PubMed ID: 27070168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of intravenous immunoglobulin preparations (IVIGs) in organ transplantation].
    Senatorski G; Hryniewiecka E
    Pol Merkur Lekarski; 2011 Jun; 30(180):417-22. PubMed ID: 21751551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
    Abolhassani H; Asgardoon MH; Rezaei N; Hammarstrom L; Aghamohammadi A
    Expert Rev Clin Immunol; 2015; 11(11):1229-43. PubMed ID: 26289377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria for the appropriate drug utilisation of immunoglobulin.
    Thürmann P; Harder S
    Pharmacoeconomics; 1996 May; 9(5):417-29. PubMed ID: 10160254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The indications for intravenous immunoglobulins in pediatric practice].
    Popescu V; Bleahu D
    Pediatrie (Bucur); 1992; 41(1):37-45. PubMed ID: 1322724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous inmunoglobulins in pediatrics].
    Panadero Esteban MI; Carcelén Andrés J; Urbieta Sanz E; Viñuales Armengol MC; Idoipe Tomás A
    Farm Hosp; 2003; 27(3):179-87. PubMed ID: 12835820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
    Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
    Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical-based assays in the bioanalysis of immunoglobulins.
    Lamari F; Anastassiou ED; Dimitracopoulos G; Karamanos NK
    J Pharm Biomed Anal; 2000 Nov; 23(6):939-46. PubMed ID: 11095294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies].
    Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K
    Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins: clinical experience and viral safety.
    Ballow M
    J Am Pharm Assoc (Wash); 2002; 42(3):449-58; quiz 458-9. PubMed ID: 12030632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America.
    Condino-Neto A; Costa-Carvalho BT; Grumach AS; King A; Bezrodnik L; Oleastro M; Leiva L; Porras O; Espinosa-Rosales FJ; Franco JL; Sorensen RU
    Allergol Immunopathol (Madr); 2014; 42(3):245-60. PubMed ID: 23333411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review.
    Pastori D; Esposito A; Mezzaroma I
    Int Rev Immunol; 2011 Feb; 30(1):44-66. PubMed ID: 21171862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
    Rütter A; Luger TA
    J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.